Press Releases

Date Title and Summary Additional Formats
Toggle Summary Allergan Enters Into Licensing Agreement with Assembly Biosciences to Obtain Worldwide Rights to Microbiome Gastrointestinal Development Programs
-- Expands Allergan's Innovative GI Pipeline with ABI-M201 and ABI-M301, Preclinical Compounds Targeting Ulcerative Colitis and Crohn's Disease, as well as Future Compounds for Irritable Bowel Syndrome -- DUBLIN, Ireland and INDIANAPOLIS , Jan. 09, 2017 (GLOBE NEWSWIRE) -- Allergan plc (NYSE:AGN)
View HTML
Toggle Summary Assembly Biosciences Announces $15.75 Million Registered Direct Offering
NEW YORK , Oct. 1, 2014 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Assembly) (Nasdaq:ASMB) announced today that on October 1, 2014 , it entered into an agreement with institutional investors for the sale of 1,959,000 shares of its common stock at the price of $8.04 per share, resulting in
View HTML
Toggle Summary Assembly Biosciences Announces 2017 AASLD Presentations
INDIANAPOLIS , Oct. 02, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the
View HTML
Toggle Summary Assembly Biosciences Announces ABI-H0731 Phase 1b Interim Data Accepted as a Late-Breaker Poster at The International Liver Congress™ (EASL)
INDIANAPOLIS and SAN FRANCISCO , March 28, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders
View HTML
Toggle Summary Assembly Biosciences Announces Additions to Management Team and Board of Directors
Accomplished industry veterans further strengthen leadership team; Graham Cooper joins as CFO and COO and Helen S. Kim is appointed to Board of Directors INDIANAPOLIS , March 12, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a
View HTML
Toggle Summary Assembly Biosciences Announces First Quarter 2018 Financial Results
INDIANAPOLIS and SAN FRANCISCO , May 07, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral synthetic live biotherapeutics for
View HTML
Toggle Summary Assembly Biosciences Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
INDIANAPOLIS and SAN FRANCISCO , June 08, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral synthetic live biotherapeutics for
View HTML
Toggle Summary Assembly Biosciences Announces June Conference Presentations
Also Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
View HTML
Toggle Summary Assembly Biosciences Announces Key Additions to Microbiome Team
Assembly Adds Key Scientific, Manufacturing and Strategy Leadership to Support Its Expanding Microbiome Platform
View HTML
Toggle Summary Assembly Biosciences Announces Participation in HBV Scientific Meetings in China and South Korea
INDIANAPOLIS , Sept. 21, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biological therapeutics for disorders associated with the human
View HTML